Hidonac (Acetylcysteine)

Hidonac is indicated for two primary clinical situations where acetylcysteine provides therapeutic benefit.

• Treatment of acetaminophen (paracetamol) overdose to prevent hepatic injury.
• Mucolytic therapy in acute or chronic respiratory diseases with thickened secretions.
• Adjunctive use in cystic fibrosis to improve airway clearance.
• Supportive care in bronchiolitis or pneumonia when mucus plugging is present.
• Pre‑operative preparation to reduce airway secretions in patients undergoing surgery.
• Use in inhalation injury to facilitate clearance of soot and inflammatory debris.
• Administration in severe asthma exacerbations when standard bronchodilators fail to clear viscous secretions.

• Acetylcysteine acts as a precursor for intracellular glutathione, restoring antioxidant capacity in epithelial cells. By supplying cysteine, it promotes the synthesis of glutathione, which directly reduces disulfide bonds within mucin glycoproteins. This cleavage lowers the molecular weight and viscosity of mucus, facilitating ciliary transport and expectoration. In cases of acetaminophen toxicity, the increased glutathione conjugates the reactive metabolite N‑acetyl‑p‑benzoquinone imine, enhancing its detoxification.

Acetylcysteine administered intravenously may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common

• Nausea or vomiting, usually mild and self‑limiting
• Mild rash or pruritus at the infusion site
• Transient flushing or sensation of warmth during infusion
• Headache that resolves after the dose
• Elevated liver enzymes (asymptomatic) detected on laboratory testing
• Transient mild fever without other signs of infection

Serious

• Anaphylactoid or anaphylactic reactions, which may include hypotension, bronchospasm, and urticaria
• Severe bronchospasm or respiratory distress requiring supplemental oxygen or ventilation support
• Acute hemolysis in patients with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency
• Persistent hypotension that necessitates vasopressor therapy
• Seizures or altered mental status, particularly in overdose situations
• Acute renal impairment manifested by rising creatinine levels

When using Hidonac, clinicians should observe several precautionary measures to minimize risk and ensure safe administration.

• Assess patient history for hypersensitivity to acetylcysteine or sulfhydryl compounds.
• Verify liver function status, especially in patients with chronic hepatic disease.
• Monitor vital signs and respiratory status during and after infusion.
• Adjust infusion rate in patients with asthma or reactive airway disease.
• Use caution in individuals with known G6PD deficiency due to risk of hemolysis.
• Perform baseline and periodic laboratory tests, including liver enzymes and renal function.

Intravenous acetylcysteine can interact with other medicines, and awareness of these interactions helps guide safe co‑administration.

Avoid

• Concurrent use with nitroglycerin or other vasodilators that may potentiate hypotension.
• Simultaneous administration with activated charcoal, which can reduce acetylcysteine absorption in oral formulations (not relevant for IV but noted for overall care).

Use with caution

• Anticoagulants (e.g., warfarin) – monitor coagulation parameters as acetylcysteine may affect platelet function.
• Loop diuretics – monitor electrolyte balance and renal function.
• Other mucolytics – assess cumulative effect on mucus clearance.
• Chemotherapeutic agents (e.g., cyclophosphamide) – observe for enhanced toxicity.
• Radiographic contrast media – watch for renal impairment when combined.